Back to Journals » Metalloproteinases In Medicine » Volume 3

Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine

Authors Boucher B

Received 12 August 2016

Accepted for publication 16 August 2016

Published 19 September 2016 Volume 2016:3 Pages 75—79

DOI https://doi.org/10.2147/MNM.S119588

Checked for plagiarism Yes

Editor who approved publication: Dr Yoshifumi Itoh


Barbara J Boucher

The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
 
The review by Mohan et al1 is interesting because increased activity of various matrix metalloproteinases (MMPs), increasing the severity of tissue damage, is found in many different disease processes. To reduce tissue-damaging overactivity of these tissue remodeling enzymes, one can reduce MMP secretion, or increase the secretion of tissue inhibitors of MMPs (TIMPs); developing therapeutic agents, or boosting natural tissue MMP inhibitors, is therefore an important and worthwhile project. However, this review does not mention vitamin D which is essential for bone health and is known to regulate bone growth through MMP modulation,2 and increasingly reported as suppressing the overactivity of certain MMPs, especially MMP-2 and MMP-9, in many pathological disorders (although vitamin A can also modulate some MMPs). 
 
View the original paper by Mohan and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]